Study guide
23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols
EDAIC Part I European Diploma in Anaesthesiology and Intensive Care
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The EDAIC Part I Examination
1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy
2 Chapter 2: Anatomy for Anaesthesia and Intensive Care
2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart
3 Chapter 3: Respiratory and Cardiovascular Physiology
3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics
4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
5 Chapter 5: Endocrine and Haematological Physiology
5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders
6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric
6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation
7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics
7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity
8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics
8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents
9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics
9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy
10 Chapter 10: Haematological and Internal Medicine Pharmacology
10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions
11 Chapter 11: Physics, Clinical Measurement and Medical Equipment
11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring
12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis
12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units
13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal
13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)
14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management
14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
15 Chapter 15: Coexisting Disease and Preoperative Investigations
15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia
16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury
17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia
17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia
18 Chapter 18: Anaesthetic Complications and Specialty Settings
18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery
19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management
19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support
20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes
21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies
22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics
23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration
24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies
24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy
25 Chapter 25: Burns, Environmental Emergencies and Patient Transport
25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill
23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols
Key Takeaways Explain This Topic AI
The primary trauma survey follows the (C)ABCDE sequence, prioritizing catastrophic external hemorrhage control with limb tourniquets and wound packing prior to airway instrumentation with in-line cervical stabilization.
The lethal triad of trauma comprises hypothermia (<35°C), acidosis (pH < 7.20), and trauma-induced coagulopathy (TIC); reducing arterial pH from 7.4 to 7.0 decreases factor VIIa-tissue factor complex activity by over 90%.
Damage control resuscitation combines permissive hypotension (target SBP 80-90 mmHg, contraindicated in traumatic brain injury where SBP must remain >= 100-110 mmHg) with early balanced hemostatic blood component administration.
The CRASH-2 trial established that early intravenous tranexamic acid (1 g bolus over 10 min followed by 1 g over 8 h) significantly reduces all-cause mortality when given within 3 hours of trauma; starting it beyond 3 hours increases death due to bleeding.
Last updated: October 2026
23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols
Exsanguinating hemorrhage remains the leading cause of preventable mortality following major trauma. Modern trauma resuscitation has evolved from aggressive crystalloid volume expansion to the integrated paradigm of Damage Control Resuscitation (DCR) , combining permissive hypotension, immediate hemorrhage control, balanced hemostatic transfusion, and prevention of the lethal triad.
1. Primary Survey: The (C)ABCDE Paradigm
The Advanced Trauma Life Support (ATLS) algorithm incorporates catastrophic hemorrhage control as the foremost clinical priority: +--------------------------------------------------------------------------+
- | (C)ABCDE RESUSCITATION SEQUENCE |
- +--------------------------------------------------------------------------+
- | (C) | Catastrophic Hemorrhage: Arrest life-threatening external bleeding |
- | | with tourniquets, junctional clamps, and hemostatic packing. |
- +-----+--------------------------------------------------------------------+
- | A | Airway with Cervical Spine Restriction: Manual in-line |
- | | stabilization (MILS), video-laryngoscopy, or surgical airway. |
- +-----+--------------------------------------------------------------------+
- | B | Breathing and Ventilation: Exclude tension pneumothorax, open |
- | | chest wounds, and massive hemothorax; finger thoracostomy. |
- +-----+--------------------------------------------------------------------+
- | C | Circulation and Internal Hemorrhage: eFAST examination, pelvic |
- | | binder placement, wide-bore IV access, balanced blood transfusion. |
- +-----+--------------------------------------------------------------------+
- | D | Disability: Neurological evaluation (GCS, pupil symmetry, spinal). |
- +-----+--------------------------------------------------------------------+
- | E | Exposure and Environment: Complete visualization while strictly |
- | | maintaining normothermia (prevent hypothermia). |
- +-----+--------------------------------------------------------------------+
Airway Control with Cervical Spine Restriction: Ensure manual in-line stabilization (MILS) during airway instrumentation. Minimize cervical movement by releasing the anterior collar piece while maintaining axial stabilization. Induction agents must be drastically down-titrated in hypovolemia (e.g. ketamine 0.5 – 1.0 mg/kg 0.5\text{--}1.0\text{ mg/kg} 0.5 – 1.0 mg/kg or etomidate 0.15 – 0.2 mg/kg 0.15\text{--}0.2\text{ mg/kg} 0.15 – 0.2 mg/kg ) to avoid post-induction cardiovascular collapse.
Decompression of Tension Pneumothorax: Immediate finger thoracostomy or needle decompression using a large-bore cannula ( 14 – 16 G 14\text{--}16\text{ G} 14 – 16 G ) at the fourth or fifth intercostal space just anterior to the mid-axillary line in adults (ATLS 10th edition; the second intercostal space in the mid-clavicular line remains the site in children), followed promptly by chest drain placement.
Circulatory Assessment: Perform an extended Focused Assessment with Sonography for Trauma (eFAST) to identify free fluid in the right upper quadrant (Morison's pouch), left upper quadrant (splenorenal recess), pelvis, pericardium, and pleural spaces. In unstable pelvic fractures, immediately apply a pelvic binder centered over the greater trochanters (not the iliac crests).
2. ATLS Classification of Hemorrhagic Shock
Parameter Class I Class II (Mild) Class III (Moderate) Class IV (Severe)
Blood Loss (mL in 70kg adult) < 750 mL <750\text{ mL} < 750 mL 750 – 1500 mL 750\text{--}1500\text{ mL} 750 – 1500 mL 1500 – 2000 mL 1500\text{--}2000\text{ mL} 1500 – 2000 mL > 2000 mL >2000\text{ mL} > 2000 mL
Blood Loss (% blood volume) < 15 % <15\% < 15% 15 – 30 % 15\text{--}30\% 15 – 30% 30 – 40 % 30\text{--}40\% 30 – 40% > 40 % >40\% > 40%
Heart Rate ( min − 1 {\min}^{-1} min − 1 ) < 100 <100 < 100 100 – 120 100\text{--}120 100 – 120 120 – 140 120\text{--}140 120 – 140 > 140 >140 > 140
- Blood Pressure Normal Normal Decreased (Hypotension) Severely decreased
- Pulse Pressure Normal Narrowed Narrowed Severely narrowed
Respiratory Rate ( min − 1 {\min}^{-1} min − 1 ) 14 – 20 14\text{--}20 14 – 20 20 – 30 20\text{--}30 20 – 30 30 – 40 30\text{--}40 30 – 40 > 35 >35 > 35
Urine Output ( mL/h \text{mL/h} mL/h ) > 30 >30 > 30 20 – 30 20\text{--}30 20 – 30 5 – 15 5\text{--}15 5 – 15 Negligible
Mental Status Slightly anxious Mildly anxious Confused, agitated Lethargic, comatose
Base Deficit (ATLS 10th ed.) 0 0 0 to − 2 mEq/L -2\text{ mEq/L} − 2 mEq/L − 2 -2 − 2 to − 6 mEq/L -6\text{ mEq/L} − 6 mEq/L − 6 -6 − 6 to − 10 mEq/L -10\text{ mEq/L} − 10 mEq/L − 10 mEq/L -10\text{ mEq/L} − 10 mEq/L or less
Note: The ATLS 10th edition (2018) presents these signs as directional changes rather than fixed thresholds and adds base deficit; the numeric values above are traditional teaching values.
Clinical Pearl: Class III shock represents the critical tipping point where compensatory vasoconstriction and tachycardia fail to preserve cardiac output, precipitating overt systemic hypotension and tissue hypoperfusion.
- 3. The Lethal Triad and Trauma-Induced Coagulopathy (TIC) [ THE LETHAL TRIAD OF TRAUMA ]
- |
- +--------------------------+--------------------------+
- | |
- [ Hypothermia ] <====================================> [ Acidosis ]
- Core temp <35°C - Base excess <-6 mmol/L
- Clotting enzyme kinetics - Inhibits factor complexes
- drop ~10% per 1°C (FVIIa/TF drops 90% at pH 7.0)
- ^ ^
- | |
- +=================> [ Coagulopathy ] <================+
- Glycocalyx shedding (syndecan-1)
- Fibrinogen consumption
- Hyperfibrinolysis (tPA excess)
Hypothermia ( < 35 °C <35\text{°C} < 35 °C ): Cold exposure, exposure of body cavities, and rapid infusion of unwarmed fluids impair hemostasis. The enzyme kinetics of the coagulation cascade decline linearly by approximately 10% per 1 °C 1\text{°C} 1 °C drop in temperature. Platelet activation, adhesion (glycoprotein Ib-IX), and aggregation (glycoprotein IIb/IIIa) are severely paralyzed.
Metabolic Acidosis ( p H < 7.20 pH < 7.20 p H < 7.20 , Base Excess < − 6 mmol/L < -6\text{ mmol/L} < − 6 mmol/L ): Lactic acidosis secondary to tissue hypoperfusion directly suppresses clotting factor complex assembly on platelet phospholipid surfaces. At a p H pH p H of 7.0, the enzymatic activity of the factor VIIa / tissue factor complex decreases by more than 90% , and prothrombinase complex activity falls by 70%.
Trauma-Induced Coagulopathy (TIC): TIC is an endogenous, phenotypic coagulopathy present in up to one-third of major trauma patients prior to significant IV fluid administration. Driven by tissue hypoperfusion and sympathoadrenal activation, the endothelial glycocalyx sheds syndecan-1 and heparan sulfates (endogenous auto-heparinization). Thrombomodulin expression surges, activating Protein C, which irreversibly degrades factors Va and VIIIa while neutralizing plasminogen activator inhibitor-1 (PAI-1), culminating in uninhibited hyperfibrinolysis and profound consumptive hypofibrinogenemia.
4. Principles of Damage Control Resuscitation (DCR)
Damage Control Resuscitation is an integrated clinical strategy designed to sustain vital organ perfusion while preventing exacerbation of the lethal triad.
Permissive Hypotension (Deliberate Hypotension)
Target: Maintain a systolic blood pressure of 80 – 90 mmHg 80\text{--}90\text{ mmHg} 80 – 90 mmHg (or Mean Arterial Pressure of 50 – 60 mmHg 50\text{--}60\text{ mmHg} 50 – 60 mmHg , or palpable radial pulse) until definitive surgical or endovascular hemostasis is attained.
Rationale: Aggressive fluid administration elevates hydrostatic pressure, "popping nascent clots" and worsening dilutional coagulopathy and hypothermia.
Crucial Exception: Traumatic Brain Injury (TBI): Permissive hypotension is strictly contraindicated in patients with known or suspected severe TBI. Autoregulation is lost, and cerebral perfusion pressure ( C P P = M A P − I C P CPP = MAP - ICP CPP = M A P − I CP ) becomes entirely pressure-dependent. Even brief episodes of hypotension ( S B P < 90 mmHg SBP < 90\text{ mmHg} SBP < 90 mmHg ) double mortality in TBI. In neurotrauma, the target systolic blood pressure must be maintained at ≥ 100 – 110 mmHg \ge 100\text{--}110\text{ mmHg} ≥ 100 – 110 mmHg (or M A P ≥ 80 mmHg MAP \ge 80\text{ mmHg} M A P ≥ 80 mmHg ).
Damage Control Surgery (DCS)
Abbreviated initial surgical intervention ( < 60 – 90 minutes <60\text{--}90\text{ minutes} < 60 – 90 minutes ) dedicated strictly to: 1) controlling surgical hemorrhage (packing, vascular shunts); 2) controlling contamination (stapling bowel perforations); and 3) temporary abdominal closure (vacuum packs). Definitive anatomical reconstruction is deferred while the patient is transferred to the ICU for correction of hypothermia, acidosis, and coagulopathy.
- 5. Massive Transfusion Protocols, Viscoelastic Testing, and TXA
- Definitions of Massive Transfusion
Replacement of ≥ 1 \ge 1 ≥ 1 complete circulating blood volume within 24 hours (~70 mL/kg in adults).
Transfusion of > 10 units >10\text{ units} > 10 units of packed red blood cells (PRBC) within 24 hours.
Transfusion of > 4 units >4\text{ units} > 4 units of PRBC within 1 hour with anticipated ongoing bleeding.
Replacement of > 50 % >50\% > 50% of total blood volume within 3 hours.
Empirical 1:1:1 Ratio vs Goal-Directed Viscoelastic Resuscitation
The PROPPR trial (2015) compared fixed-ratio resuscitation with 1 unit of PRBC : 1 unit of Fresh Frozen Plasma (FFP) : 1 unit of Platelets (e.g. 6 PRBC : 6 FFP : 1 apheresis platelet pack) against a 1:1:2 ratio. There was no significant difference in all-cause mortality at 24 hours or 30 days, but the 1:1:1 group achieved haemostasis more often and had fewer deaths from exsanguination within 24 hours.
Modern European trauma guidelines strongly recommend viscoelastic hemostatic assays (ROTEM / TEG) to drive individualized, goal-directed resuscitation: +----------------+-------------------------------+----------------------------+
- | ROTEM TEST | PATHOLOGY IDENTIFIED | DIRECTED INTERVENTION |
- +----------------+-------------------------------+----------------------------+
- | EXTEM CT >80s | Clotting factor deficiency | Fresh Frozen Plasma (FFP) |
- | | or delayed thrombin generation| or 4-factor PCC (25 IU/kg) |
- +----------------+-------------------------------+----------------------------+
- | FIBTEM A10 | Severe hypofibrinogenemia | Fibrinogen Concentrate |
- | <10 mm | (<1.5-2.0 g/L) | (2-4 g) or Cryoprecipitate |
- +----------------+-------------------------------+----------------------------+
- | EXTEM A10 <40mm| Thrombocytopenia or platelet | Platelet Concentrate |
- | (normal FIBTEM)| dysfunction | (1 adult pool) |
- +----------------+-------------------------------+----------------------------+
- | EXTEM ML >15% | Pathological systemic | Tranexamic Acid (TXA) |
- | | hyperfibrinolysis | 1 g IV bolus |
- +----------------+-------------------------------+----------------------------+
- Tranexamic Acid (TXA) and the CRASH-2 Trial
Mechanism: Synthetic lysine analogue that competitively binds plasminogen lysine-binding sites, preventing plasminogen activation and fibrin degradation.
CRASH-2 Evidence: Administration of TXA ( 1 g 1\text{ g} 1 g IV over 10 minutes, followed by 1 g 1\text{ g} 1 g IV infusion over 8 hours ) in bleeding trauma patients within 3 hours of injury significantly reduced all-cause mortality (RR 0.91; p = 0.0035 p=0.0035 p = 0.0035 ) and death due to bleeding (RR 0.85; p = 0.0077 p=0.0077 p = 0.0077 ).
Critical Time Dependence: When administered > 3 hours >3\text{ hours} > 3 hours after injury , TXA increased the risk of death due to bleeding (RR 1.44; p = 0.004 p=0.004 p = 0.004 ), without an excess of vascular occlusive events. TXA should not be started if > 3 hours >3\text{ hours} > 3 hours have elapsed since injury.
6. Complications of Massive Blood Transfusion
Citrate Toxicity and Acute Hypocalcemia: Citrate anticoagulant in PRBCs and FFP chelates ionized calcium and magnesium. Hepatic clearance of citrate is impaired by hypothermia and hypoperfusion. Ionized calcium levels drop ( C a 2 + < 0.9 mmol/L Ca^{2+} < 0.9\text{ mmol/L} C a 2 + < 0.9 mmol/L ), precipitating myocardial depression, blunted systemic vascular resistance, prolonged QT intervals, and coagulopathic failure (calcium is Factor IV). Management: Prophylactically infuse 10 mL 10\text{ mL} 10 mL of 10% calcium chloride IV for every 2 – 4 units 2\text{--}4\text{ units} 2 – 4 units of blood products transfused.
Hyperkalemia: Extracellular potassium concentrations in stored PRBCs rise by approximately 1 mmol/L/day 1\text{ mmol/L/day} 1 mmol/L/day , exceeding 25 – 30 mmol/L 25\text{--}30\text{ mmol/L} 25 – 30 mmol/L near expiration ( 35 – 42 days 35\text{--}42\text{ days} 35 – 42 days ). Rapid, pressurized infusion can precipitate lethal ventricular arrhythmias.
Hypothermia: Transfusing cold PRBCs ( 4 °C 4\text{°C} 4 °C ) directly into the central circulation causes cardiac dysrhythmias and worsens coagulopathy. Use high-flow fluid warmers (e.g. Belmont, Level 1) capable of delivering fluids at 37 – 40 °C 37\text{--}40\text{°C} 37 – 40 °C at rates > 500 mL/min >500\text{ mL/min} > 500 mL/min .
TRALI vs TACO Differential Diagnosis:
Feature TRALI (Acute Lung Injury) TACO (Circulatory Overload)
Mechanism Non-cardiogenic; donor anti-HLA/HNA antibodies activate recipient lung neutrophils Cardiogenic hydrostatic pulmonary edema; fluid volume and rate overload
- Onset Within 6 hours of transfusion Within 6 hours (often during infusion)
- Blood Pressure Normal or hypotension Hypertension , wide pulse pressure
- Jugular Venous Pulse Normal or low Elevated (CVP > 15 mmHg >15\text{ mmHg} > 15 mmHg )
- Cardiac Biomarkers Normal BNP / NT-proBNP Significantly elevated BNP
- Chest Radiography Bilateral patchy infiltrates Cardiomegaly, pleural effusions, Kerley B lines
- Response to Diuretics Minimal or worsens shock Prompt improvement with furosemide